The Biologics research program helps Canadian firms de-risk biologics development and accelerate time to market by offering innovative R&D expertise and state-of-the-art facilities. The program offers unparalleled expertise in the following three areas of biologics development: candidate design, selection, and optimization; bioprocess development; and, performance characterization. The program partners with Canadian small and medium-sized enterprises to de-risk a pipeline of biologics and accelerate their progress to market.
The Vaccines research program assists Canadian industry in developing vaccines in the areas of infectious and chronic diseases. This is done through research and development collaboration and services, as well as licensing. By co-developing vaccines for infectious and chronic diseases, NRC helps Canadian companies with vaccine candidate design, targeting, production, and evaluation. This research program responds to growing health care pressures and supports sustainable economic development.
The Therapeutics beyond brain barriers research program addresses various brain diseases and enables partners' large molecules to cross the blood-brain barrier. This is accomplished through co-development agreements where partners’ molecules are coupled to NRC's blood-brain barrier carriers, which are single domain antibodies. This research program’s core activities rest on three pillars of expertise: generation of carriers, coupling and conjugation strategies, and evaluation of candidates in brain barrier models using biomarkers and other tools.
